Understanding Alzheimer’s Risk Factors Associated with the Prevalence of US Populations and Women
DOI:
https://doi.org/10.47611/jsrhs.v11i1.2269Keywords:
Alzheimer, Risks, Prevalance, Genetic Risk, Behavioral Risk, Environmental Risk, Therapeutic treatments, DementiaAbstract
Alzheimer's disease (AD), a fatal neurological disease, is the 6th leading cause of death in the United States 43, affecting millions of people. This is a great concern as, by 2060, the number could grow to 13.8 million if no cure is discovered0. Despite sophisticated research and technology, finding a solution in the near future appears unattainable due to financing and the brain's complexity. Due to Alzheimer's disease affecting millions of people, the goal of this research is to inform and educate people about the risk factors, prevalence in individuals, and therapeutic treatments available early on for this disease so that one can minimize their risk of developing it. People are unaware of genetic, behavioral, and environmental vulnerabilities that raise their chances of acquiring the disease chronically, which is why this disease has affected millions and is one of the leading causes of mortality. People would avoid these risks if they were aware of them early on. Methods to reduce the chance of developing Alzheimer's disease are discovered through examining the risks and existing therapeutic treatments, as well as analyzing the prevalence of the disease in different ethnic groups and women in the United States through a variety of sources. The findings identified the major causes of Alzheimer's disease, why particular ethnic groups are more susceptible to the disease, and why women are disproportionately impacted by the disease compared to males. Knowing all of this, plus the therapies, can help reduce the number of AD cases in the US.
Downloads
References or Bibliography
World Health Organization: WHO. “Dementia.” Who.int, World Health Organization: WHO, 21 Sept. 2020, www.who.int/news-room/fact-sheets/detail/dementia. Accessed 28 Aug. 2021.
Melinda. “Dementia Symptoms, Types, and Causes.” HelpGuide.org, 3 Nov. 2018, www.helpguide.org/articles/alzheimers-dementia-aging/living-with-dementia.htm. Accessed 28 Aug. 2021.
“Dementia vs. Alzheimer’s Disease: What Is the Difference?” Alzheimer’s Disease and Dementia, 2021, www.alz.org/alzheimers-dementia/difference-between-dementia-and-alzheimer-s. Accessed 28 Aug. 2021.
“What Is Alzheimer’s Disease? | Columbia | Center of Excellence in Alzheimer’s Disease.” Columbia.edu, 2021, cead.cumc.columbia.edu/content/what-alzheimers-disease. Accessed 28 Aug. 2021.
“Stages of Alzheimer’s.” Alzheimer’s Disease and Dementia, 2021, www.alz.org/alzheimers-dementia/stages. Accessed 28 Aug. 2021.
NHS Choices. Symptoms - Alzheimer’s Disease. 2021, www.nhs.uk/conditions/alzheimers-disease/symptoms/. Accessed 28 Aug. 2021.
https://www.facebook.com/NIHAging. “What Is Alzheimer’s Disease?” National Institute on Aging, 2021, www.nia.nih.gov/health/what-alzheimers-disease Accessed 28 Aug. 2021.
“The Discovery of Alzheimer’s Disease.” Dialogues in Clinical Neuroscience, vol. 5, no. 1, Mar. 2003, pp. 101–108, www.ncbi.nlm.nih.gov/pmc/articles/PMC3181715/, 10.31887/dcns.2003.5.1/hhippius. Accessed 28 Aug. 2021.
https://www.facebook.com/NIHAging. “What Happens to the Brain in Alzheimer’s Disease?” National Institute on Aging, 2017, www.nia.nih.gov/health/what-happens-brain-alzheimers-disease. Accessed 28 Aug. 2021.
“U.S. Burden of Alzheimer’s Disease, Related Dementias to Double by 2060.” CDC, 1 Jan. 2016, www.cdc.gov/media/releases/2018/p0920-alzheimers-burden-double-2060.html. Accessed 28 Aug. 2021. 11.“Hormones and Dementia.” Alzheimer’s Society, 2015, www.alzheimers.org.uk/about-dementia/risk-factors-and-prevention/hormones-and-dementia. Accessed 28 Aug. 2021.
“Is Alzheimer’s Genetic?” Alzheimer’s Disease and Dementia, 2021, www.alz.org/alzheimers-dementia/what-is-alzheimers/causes-and-risk-factors/genetics. Accessed 28 Aug. 2021.
Liao, Fan, et al. “Apolipoprotein E Metabolism and Functions in Brain and Its Role in Alzheimerʼs Disease.” Current Opinion in Lipidology, Dec. 2016, p. 1, www.ncbi.nlm.nih.gov/pmc/articles/PMC5213812/, 10.1097/mol.0000000000000383. Accessed 28 Aug. 2021.
Gomez-Pinilla, Fernando. “How Does the Brain Use Food as Energy?” Brainfacts.org, 2012, www.brainfacts.org/ask-an-expert/how-does-the-brain-use-food-as-energy. Accessed 28 Aug. 2021.
5. Alz.Org, 2021, https://www.alz.org/media/documents/alzheimers-facts-and-figures-2019-r.pdf. Accessed 28 Aug 2021.
Keene, C Dirk, et al. “Apolipoprotein E Isoforms and Regulation of the Innate Immune Response in Brain of Patients with Alzheimer’s Disease.” Current Opinion in Neurobiology, vol. 21, no. 6, Dec. 2011, pp. 920–928, www.ncbi.nlm.nih.gov/pmc/articles/PMC3237894/, 10.1016/j.conb.2011.08.002. Accessed 28 Aug. 2021.
Husain, Mohammed Amir, et al. “APOE and Alzheimer’s Disease: From Lipid Transport to Physiopathology and Therapeutics.” Frontiers in Neuroscience, vol. 15, 17 Feb. 2021, www.frontiersin.org/articles/10.3389/fnins.2021.630502/full, 10.3389/fnins.2021.630502. Accessed 28 Aug. 2021.
Liu, Chia-Chen, et al. “Apolipoprotein E and Alzheimer Disease: Risk, Mechanisms and Therapy.” Nature Reviews Neurology, vol. 9, no. 2, 8 Jan. 2013, pp. 106–118, www.ncbi.nlm.nih.gov/pmc/articles/PMC3726719/, 10.1038/nrneurol.2012.263. Accessed 28 Aug. 2021.
Makin, Simon. “The Amyloid Hypothesis on Trial.” Nature, vol. 559, no. 7715, July 2018, pp. S4–S7, www.nature.com/articles/d41586-018-05719-4, 10.1038/d41586-018-05719-4. Accessed 28 Aug. 2021.
0. Liu, Chia-Chen, et al. “Apolipoprotein E and Alzheimer Disease: Risk, Mechanisms and Therapy.” Nature Reviews Neurology, vol. 9, no. 2, 8 Jan. 2013, pp. 106–118, www.ncbi.nlm.nih.gov/pmc/articles/PMC3726719/, 10.1038/nrneurol.2012.263. Accessed 28 Aug. 2021.
Kanekiyo, Takahisa, et al. “ApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?” Neuron, vol. 81, no. 4, Feb. 2014, pp. 740–754, www.ncbi.nlm.nih.gov/pmc/articles/PMC3983361/, 10.1016/j.neuron.2014.01.045. Accessed 28 Aug. 2021.
Alz.Org, 2021, https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf. Accessed 28 Aug 2021.
Crean, Sheila, et al. “Apolipoprotein E ε4 Prevalence in Alzheimer’s Disease Patients Varies across Global Populations: A Systematic Literature Review and Meta-Analysis.” Dementia and Geriatric Cognitive Disorders, vol. 31, no. 1, 2011, pp. 20–30, www.karger.com/Article/Fulltext/321984#:~:text=As%20seen%20in%20figure%204, 10.1159/000321984.
“APOE and Gender | Cognitive Vitality | Alzheimer’s Drug Discovery Foundation.” Alzdiscovery.org, 2017, www.alzdiscovery.org/cognitive-vitality/blog/apoe-and-gender. Accessed 28 Aug. 2021.
Explain, May. “Finding May Explain Why Women More Likely Develop Alzheimer’s.” Science | AAAS, 14 Apr. 2014, www.sciencemag.org/news/2014/04/finding-may-explain-why-women-more-likely-develop-alzheimers. Accessed 28 Aug. 2021.
Huentelman, Matt. “Sleep and Dementia Prevention: Improving Brain Health.” MindCrowd, 15 Mar. 2021, blog.mindcrowd.org/sleep-and-dementia-prevention-improving-brain-health/. Accessed 28 Aug. 2021.
Joy, Rebecca. “How Does Cortisol Affect Your Sleep?” Healthline, Healthline Media, 10 July 2020, www.healthline.com/health/cortisol-and-sleep#how-it-affects-sleep. Accessed 28 Aug. 2021.
McKnight-Eily, Lela R., et al. “Racial and Ethnic Disparities in the Prevalence of Stress and Worry, Mental Health Conditions, and Increased Substance Use among Adults during the COVID-19 Pandemic — United States, April and May 2020.” MMWR. Morbidity and Mortality Weekly Report, vol. 70, no. 5, 5 Feb. 2021, pp. 162–166, www.cdc.gov/mmwr/volumes/70/wr/mm7005a3.htm, 10.15585/mmwr.mm7005a3. Accessed 28 Aug. 2021.
"Race and Stress – the Alternative Hypothesis.” Thealternativehypothesis.org, 2021, thealternativehypothesis.org/index.php/2016/04/15/race-and-stress/. Accessed 28 Aug. 2021.
“Do Women Need More Sleep than Men? | Sleep Foundation.” Sleep Foundation, 22 Jan. 2021, www.sleepfoundation.org/women-sleep/do-women-need-more-sleep-than-men. Accessed 28 Aug. 2021. 31. “Environment, Ethics, and Human Health.” The Hastings Center, 11 May 2018, www.thehastingscenter.org/briefingbook/environmental-health/. Accessed 28 Aug. 2021.
Site designed and developed by bka interactive ltd, Auckland, New Zealand (www.bka.co.nz. “Learning New Things – the Benefits | Health Navigator NZ.” Health Navigator New Zealand, Health Navigator New Zealand, 6 June 2021, www.healthnavigator.org.nz/healthy-living/l/learning-new-things-the-benefits/. Accessed 28 Aug. 2021.
Farina, Mateo P, et al. “Racial and Educational Disparities in Dementia and Dementia-Free Life Expectancy.” The Journals of Gerontology: Series B, vol. 75, no. 7, 25 Apr. 2019, pp. e105–e112, www.ncbi.nlm.nih.gov/pmc/articles/PMC7530490/, 10.1093/geronb/gbz046. Accessed 28 Aug. 2021.
“Racial and Ethnic Disparities in Alzheimer’s Disease: A Literature Review.” ASPE, 2014, aspe.hhs.gov/reports/racial-ethnic-disparities-alzheimers-disease-literature-review-0. Accessed 28 Aug. 2021.
“Mild Cognitive Impairment - Symptoms and Causes.” Mayo Clinic, 2020, www.mayoclinic.org/diseases-conditions/mild-cognitive-impairment/symptoms-causes/syc-20354578. Accessed 28 Aug. 2021. 36. Letenneur, L, et al. “Are Sex and Educational Level Independent Predictors of Dementia and Alzheimer’s Disease? Incidence Data from the PAQUID Project.” Journal of Neurology, Neurosurgery & Psychiatry, vol. 66, no. 2, 1 Feb. 1999, pp. 177–183, jnnp.bmj.com/content/66/2/177, 10.1136/jnnp.66.2.177. Accessed 28 Aug. 2021.
Karp, A. “Relation of Education and Occupation-Based Socioeconomic Status to Incident Alzheimer’s Disease.” American Journal of Epidemiology, vol. 159, no. 2, 15 Jan. 2004, pp. 175–183, pubmed.ncbi.nlm.nih.gov/14718220/, 10.1093/aje/kwh018. Accessed 28 Aug. 2021.
8. Safieh, Mirna, et al. “ApoE4: An Emerging Therapeutic Target for Alzheimer’s Disease.” BMC Medicine, vol. 17, no. 1, 20 Mar. 2019, bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1299-4, 10.1186/s12916-019-1299-4. Accessed 28 Aug. 2021.
Ashford, John Wesson. “Treatment of Alzheimer’s Disease: Trazodone, Sleep, Serotonin, Norepinephrine, and Future Directions.” Journal of Alzheimer’s Disease, vol. 67, no. 3, 12 Feb. 2019, pp. 923–930, www.ncbi.nlm.nih.gov/pmc/articles/PMC6398534/, 10.3233/jad-181106. Accessed 28 Aug. 2021.
News-Medical. “Bright Light Therapy and Dementia.” News-Medical.net, 22 June 2018, www.news-medical.net/health/Bright-Light-Therapy-and-Dementia.aspx. Accessed 28 Aug. 2021.
NHS Choices. Treatment - Alzheimer’s Disease. 2021, www.nhs.uk/conditions/alzheimers-disease/treatment/. Accessed 28 Aug. 2021.
“Why Is Alzheimer’s More Likely in Women?” Alzheimers.net, 2019, www.alzheimers.net/8-12-15-why-is-alzheimers-more-likely-in-women. Accessed 28 Aug. 2021.
"Disease Of The Week - Alzheimer’S Disease". Centers For Disease Control And Prevention, 2021, https://www.cdc.gov/dotw/alzheimers/index.html#:~:text=Alzheimer's%20disease%20is%20the%20most,of%20death%20for%20all%20adults. Accessed 24 Sept 2021.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Krrishika Saxena; Sabin Nettles
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
